CDllc/CD18 (p150,95) is a/32 integrin expressed by myeloid, natural killer and certain lymphoid cells such as some cytotoxic T cell clones and B cell malignancies. We have studied the expression and function of CD11c on resting and activated B lymphocytes. Flow cytometry, immunoprecipitation, and mRNA analyses showed that cell activation with phorbol esters or with a variety of stimuli such as Staphylococcus aureus or anti-/z antibodies in combination with cytokines induced de novo CDllc/CD18 cell surface expression on most B cells while CDllb expression was not affected. Functional analysis of CDllc/CD18 on B cells revealed that it plays a dual role. First, CDllc/CD18 is implicated in B cell proliferation, as demonstrated by the ability of several anti-CDllc monoclonal antibodies to trigger comitogenic signals; and second, the newly expressed CDllc/CD18 mediates B cell binding to fibrinogen. Our data conclusively demonstrate the role of CDllc/CD18 on both B cell activation and adhesion processes.
T
he integrin family is composed by at least 15 cell surface heterodimeric glycoproteins that function in cell-cell contacts and cell-extracellular matrix interactions (reviewed in references [1] [2] [3] [4] [5] . Although originally believed to participate only in adhesion processes, recent studies indicate that integrins are also involved in cell activation phenomena (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) .
Integrins have been divided in three subfamilies that can be distinguished by their common use of a unique/3 chain noncovalently associated with several distinct c~ chains, p150,95 (CDllc/CD18), together with LFA-1 (CDlla/CD18) and Mac-1 (CDllb/CD18), belongs to the/32 integrin subfamily whose expression is restricted to leukocytes. While LFA-1 is expressed on all leukocytes, Mac-1 and p150,95 are expressed mainly by granulocytes, monocytes and NK cells (16, 17) . Moreover, CDllc/CD18 is present on dendritic cells (18, 19) , certain cytotoxic T cell clones (20) , and some lymphocytes of the B cell lineage like those of the hairy cell leukemia (HCL) 1 (21) . Coexpression of Mac-1 and p150,95 by some B cell chronic lymphocytic leukemias (B-CLL) has also been reported (22) . CDllc/CD18 has been described participating in a number of adhesion phenomena such as binding to the During activation, B cells undergo a number of changes on the expression of their different surface antigens (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) . Since Mac-1 and p150,95 are expressed by certain transformed B cells, we explored whether these two integrins could be induced during in vitro activation of normal B cells. The data reported here demonstrate that cell surface expression of CDllc/CD18, but not CDllb/CD18, is induced during activation of purified B lymphocytes. The involvement of CDllc/CD18 on B cell activation is highlighted by the capacity of CDllc mAbs to trigger comitogenic signals on B lymphocytes. In addition, the expression of CD11c/CD18 also confers flbrinogen binding ability to B cells.
Dr. Schwarting (Thomas Jefferson University, Philadelphia, PA) (S-HCL 3 mAb, IgG2a). TS1/11 mAb directed to CD11a chain, TS1/18 mAb against the 82 integrin, and Bear 1 mAb directed to CD11b molecule were previously described (34, 35) . TS2/18 mAb is directed against the CD2 antigen. Anti-CD69 TP1/8, anti-CD45 D3/9, and anti-CD49d (VLA-c~4) HP2/1 mAbs were obtained in our laboratory (36) (37) (38) . F(ab')2 fragments of HC1/1 mAb were obtained upon pepsine treatment as described (39) .
Cells and Cell Cultures. Tonsillar B cells were obtained from children 4-12 yr old undergoing routine tonsillectomy. Mononuclear cells were isolated by Ficoll-Hypaque (Pharmacia Fine Chemicals, Uppsala, Sweden) centrifugation and enriched for B cells by rosetting with 2-aminoethyl-isothiouronium bromide (AET) (Sigma Chemical Co., St. Louis, MO)-treated sheep erythrocytes (Biomerieux, Marcy-12Etoile, France). The resulting B cell-enriched population was >95% CD19 + and CD20 § and <2% CDllb § and CD2 +.
In some experiments, tonsillar B cells were separated over a Percoll (Pharmacia Fine Chemicals) discontinous gradient on five bands that layered from medium to 45%, 45-55%, 55-65%, 65-75%, and 75-100%. Then, each fraction was activated and assayed for flow cytometry.
Peripheral blood B cells were obtained from heparinized venous blood of normal voluntary donors. After Ficoll-Hypaque centrifugation, peripheral mononuclear cells were depleted of adherent cells by two steps of adherence incubation in plastic flasks (Costar, Cambridge, MA) at 37~ and 5% COs atmosphere for 2 h. T cell depletion was accomplished by removing the cells that rosetted with AET-treated sheep erythrocytes as described above. Cells were grown in RPMI 1640 (Whittaker M.A. Bioproducts, Walkersville, MD) supplemented with 10% FCS (Biochrom; Seromed, Berlin, Germany), 2 mM r-glutamine (Whittaker M.A. Bioproducts), 50 U/ml of penicillin, and 50/~g/ml of streptomicin (Whittaker M.A. Binproducts). This medium will be referred as complete medium.
Reagents. Human rlL-2 and rlFN-'y was a generous gift from Hoffman-La Roche, Inc. (Nutley, NJ). Human rib4 was kindly provided by Dr. J. de Vries (Unicet Labs., Dardilly, France) and human ffNF-cr by Labs. Andr6maco (Madrid, Spain). PMA, phorbol 12,13 dibutyrate (PDB), and F(ab')s fragments of rabbit polyclonal antibodies to human # chain were purchased from Sigma Chemical Co. Staphylococcus aureus strain Cowan I (SAC) (Pansorbin) was acquired to Calbiochem-Behring Corp. (San Diego, CA). Cytokines are used at the following doses: rIL-2, 50 U/m1; rIL-4, 600 U/m1; rTNF-ot, 100 rig/m1; rIFN-% 200 U/ml. SAC was used at a 1/104 (vol/vol) dilution. Anti-# antibodies were coated to plastic plates at 50 lzg/ml in PBS, pH 8.0, overnight at 4~ Flow Cytometry Analysis. 1.5-2 x 10 s cells were incubated with 100 #1 hybridoma culture supernatants for 30 rain at 4~ After two washes with cold PBS, the cells were stained with a goat anti-mouse F(ab')s fragment FITC (Dakopatts, Glostrup, Denmark) followed by two additional washes with cold PBS. CeU immunofluorescence was analyzed by flow cytometry using a EPICS-C (Coulter Immunology, Hialeah, FL). Fluoresceined rnicrospheres of different intensities were analyzed in both log and linear scale, and a standard conversion scale was constructed. Cell fluorescence data were collected on the log scale and converted to the linear scale for a quantitative estimation. Specific relative linear fluorescence was obtained by subtracting background linear fluorescence produced by the negative control myeloma P3X63. were coated overnight at 4~ with 100 #1 of different proteins dissolved in CO3HNa (0.1 M) at 20 #g/ml and then saturated with RPMI 1640-1% HSA for 2 h at 37~ Thereafter, plates were washed gently with medium and 1.5 x 105 cells/well in 100 ~1 were added and incubated for 30 rain at 37~ After incubation, plates were washed three times and examined in an inverted microscope by at least two independent observers. Each condition was performed on duplicate. Cells were counted from at least three fields within each well. The number of cells counted in a nonwashed well was referred as input cells. In inhibition assays, cells were incubated for 30 rain at 4~ with the different mAbs and then added to wells.
Results

Induction of CDllc Expression after B Cell Activation.
Flow cytometry was used to study the ceU surface expression pattern of the/~2 integrin family during B ceU activation. As previously described, nonactivated B cells highly expressed CDlla and CD18, whereas no significant expression of CDllb (<1%) or CDllc (<5%) was detected ( Next, we investigated whether the PMA-induced CD11c expression could be altered by other stimuli each as the polydonal activator SAC, rlL,2, rib4, rlFN-3,, rTNF-ol, or anti-# antibodies (Ab). PMA-induction of CDllc/CD18 was significantly enhanced by SAC, rTNF-ol, or polyclonal anti-# Ab (data not shown). Similarly, CDllc expression could also be obtained after treatment with more "physiological" B cell activation agents: SAC or anti-# Ab combined with cytokines were able to induce CDllc expression, although to a lesser extent than phorbol esters ( Table 1) . The induction of CDllc expression was studied at the biochemical level by immunoprecipitation from both activated and nonactivated tonsillar B cell lysates with mAbs against the different members of the B2 integrin family (Fig. 2) . While only CDlla and CD18 glycoproteins were precipitated from nonactivated B cells (Fig. 2 A) , immunoprecipitation from 3-d phorbol ester-activated tonsillar B lymphocytes revealed the presence of CDllc/CD18, with its corresponding polypeptides of 150 and 95 kD (Fig. 2 B) , thus confirming the cell surface expression of this heterodimer on activated B cells.
On neutrophils, activation is followed by a rapid increase in the cell surface expression of Mac-1 and CDllc, due to To analyze the mechanisms of induction of CDllc/CD18 B cell surface expression, the steadystate level of mRNA for both chains was determined by Northern blot. While no mRNA for CDllc was detected on resting B cells, CDllc mRNA was evident at day 2 and reached a maximum by day 3 (Fig. 3 A) . CD18 mRNA was already present on resting B cells (as expected from their LFA-1 [CDlla/CD18] constitutive expression) and also showed an increase after PMA treatment (Fig. 3 B) . The kinetics of the CDllc/CD18 appearance on the membrane and the mRNA levels for CDllc and CD18 suggest that the induced cell surface expression of CDllc/CD18 is not due to the release of a preformed pool but probably to the activation of the transcription of the CDllc gene and/or to an increase in the CDllc mRNA messenger stability.
Monoclonal Antibodies Directed to CDllc Trigger Proliferative Responses on Activated Human B Lymphocytes.
The expression of CDllc on activated B cells suggested that it could play a role in the regulation of B cell function at this stage. Since a number ofintegrins have been shown to trigger comitogenic signals on T cells (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) , the functional effect of a wide panel of CDllc mAb was tested in proliferation assays. Highly purified tonsillar B cells were cultured with PMA to induce CD11c expression and were treated with CDllc mAb. Three CDllc mAbs induced comitogenic responses ranging from 2.5-to 8-fold higher than PMA alone (Fig. 4) . HC1/1 and KB23 mAbs triggered lower mitogenic responses (2.5-4-fold) than BU15 mAb (4-to 8-fold). This CDllc-mediated proliferative response was comparable to those observed with other stimuli or mitogenic combinations such as PMA plus anti-CD69 TP1/8 or anti-CD20 1F5 mAb and rlL-2 (or rIL-4) plus PMA ( Fig. 4 ; and data not shown). The anti-CD21 HB5 mAb or the anti-CD45 D3/9 mAb, included as controls, did not affect the response induced by PMA ( Fig. 3 ; and data not shown). Other anti-CDllc mAbs such as L29, KBg0, and S-HCL 3 failed to alter the PMA-induced proliferation ( Fig. 4 ; and data not shown).
The CDllc mAb-mediated B cell proliferation was shown to be: (a) dose dependent for both mAb and phorbol ester (Fig. 5) ; (b) isotype independent, as concluded from the Ig dass of the mAb tested; and (c) Fc independent, since similar proliferation effects could be obtained with the F(ab')2 fragments of HC1/1 mAb (Pigs. 4 and 5). In addition, cross- A perfect correlation was observed between the comitogenie activity of CDllc mAbs and their inhibitory effect on B cell attachment to FG: HC1/1, KB23, and BU15 were able to trigger B cell proliferation and to inhibit the call binding to FG. This fact led us to explore whether FG had any effect, either mitogenic or inhibitory, on the CDllc mAb-mediated B cell proliferation. As shown in Table 3 , FG inhibited the proliferation induced by CDllc mAbs. The partial inhibitory effect of FG probably reflects the inaccessibility of CDllc to the added mAbs caused by the redistribution of the antigen induced by the surface-bound ligand, a fact already observed for Mac-1 (45) .
presence of a PKC activator is not required for the comitogenic signals delivered through CDllc.
B Cell Activation Induces CDllc-mediated Cell Attachment to Fibrinogen. Fibrinogen Reverts B Cell Proliferation Triggered by CD11c mAt~
Very recently, it has been reported that activated neutrophils interact with fibrinogen (F-G) through both Mac-1 (42, 43) and p150,95 (44) . To analyze the functional adhesive capacities of CD11c/CD18 in the absence of CDllb expression, FG binding assays were performed on either resting and activated B cells. As shown in Fig. 6 , PMA-treated B cells, but not nonactivated B cells, were able to interact with FG. The specific involvement of CDllc/CD18 in the B cell attachment to FG was demonstrated by the ability of CDllc and CD18 mAbs to block the binding (Fig. 6 ). Adhesiveness to collagen (COL) and to a fibronectin fragment (FN38) containing the domain recognized by VLA-4 (CD49d/CD29) integrin was included as control (32) . No inhibitory effects
Discussion
The results reported here reveal that CDllc/CD18 can be induced on purified human B cells upon activation with several stimuli such as phorbol esters or either SAC or anti-# antibodies combined with cytokines. In addition, the CDllc/CD18 integrin is involved in both B cell activation and adhesion, since mAbs against this molecule trigger B cell proliferation and block cell binding to FG.
The coexpression of CD11b and CD11c is known to be restricted to granulocytes, monocytes, and NK cells (16, 17) . CDllc expression has been also demonstrated on dendritic cells (18, 19) and on some transformed T lymphocytes (20) . Among the B cell lineage, the expression of CDllc has been reported in the HCL cells and in some B-CLL (21, 22, 46) , which are also CD11b + and CD5 + (22) . Recently, a small CD5 + CDllc + B cell subset on peripheral blood from normal donors has been detected and proposed as the normal counterpart of B-CLL cells (46) . Effect of FG in CDllc mAb-mediated B cell proliferation. FG was coated to plates at 20 gg/ml (100 gl/well) overnight at 4~ Plates were gently washed and tonsillar B cells were added and activated with PMA (2 ng/ml) and/or HC1/1 mAb (5/ig/ml). Each condition was performed by triplicate.
[3H]TdR uptake was measured at day 3. These data represent one experiment out of four different assays.
The expression of CDllc by leukemic B cells suggested that its expression could be associated with cell activation processes. This fact has been confirmed by our finding of induction of CDllc expression during B cell activation. It is worth noting the lack of induction of CDllb, as opposed to its expression by B-CLL cells, suggesting a different regulation in the expression of both CDllb and CDllc, on normal and transformed human B cells.
After activation, B cells undergo a number of phenotypic changes in the expression of their surface molecules that are closely related to the activation signal (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) . For example, only phorbol esters induce CD5 expression on B cells, whereas other stimuli such as anti-g Ab and several cytokines fail to induce this B cell activation antigen (29) . Our data demonstrate that CDllc expression is mainly induced after phorbol ester treatment, although it could also be obtained upon treatment with the more physiological B cell activation agents SAC or anti-# Ab in combination with cytokines. The slow pattern of induction of CDllc on B cells resembles that observed on U937 and HL60 myelomonocytic cell lines after PMA treatment (47) and may reflect the existence of phorbol ester responsive dements on the promoter region of the CDllc gene (A.L. Corbi, unpublished observations).
Although originally integrins were believed to participate only in adhesion processes, recent reports demonstrate that they are also involved in cell activation. Thus, comitogenic signals can be triggered through VLA-4, VLA-5, and VLA-6 on activated T cells (6) (7) (8) (9) , and the expression of certain matrix-degrading protease genes (48) and transcription factors (49) is induced through VLA-5. Moreover, other nonintegrin adhesion molecules such as CD44 homing receptor and the CD2/LFA-3 pair have been also implicated in cell activation (50) (51) (52) (53) . Our data constitutes the first evidence about the implication of integrins in B cell proliferation and further strengthens the link between adhesion and cell activation. Other/32 integrins have been also implicated in cell activation. Thus, CDllb mAbs have been reported to induce macrophage activation (54) , and both CDlla and CD18 subunits are also involved in T cell activation (10) (11) (12) (13) (14) (15) . On B cells, LFA-1 mAbs have been reported to inhibit T cell-de-pendent B cell proliferation and differentiation, although CDlla mAbs have no effect on purified B cells (55) (56) (57) (58) . These data correlate with our results about the inefficiency of the anti-CDlla TS1/ll mAbs to alter the proliferative response induced by PMA. The lack of effect of LFA-1 mAbs on B cell proliferation as compared to that observed for T cells could reflect a different role of this integrin in T and B cell activation processes. At present, we are analyzing a wider panel of CDlla mAbs to further clarify the LFA-1 involvement on B cell activation.
The comitogenic effect of CDllc mAbs does not seem to be mediated via PKC activation. Moreover, none of the mitogenic anti-CDllc mAbs induced any change in the intracellular Ca 2+ levels of activated CDllc + B cells, even when a crosslinking agent was added (A.A. Postigo, unpublished observations). Furthermore, the mitogenic response elicited by CDllc mAbs did not require the continuous presence of PKC activators, suggesting that CDllc cell surface expression is enough to allow B cell proliferation via CDllc. To the best of our knowledge, no data exist about the involvement of CDllc/CD18 on cell proliferation, and further research is required to ascertain whether this activation effect could also be observed on other CDllc-expressing cell types. The difference in the proliferative response elicited by the CDllc mAbs assayed here suggests the existence of different functional domains on CDllc. It would be of interest to correlate these functional domains with those involved in the binding of CDllc/CD18 to its endothelial ligand (59) .
Among the/32 integrins, the functional role of CDllc is the least known, and some controversy exists about its ligandbinding abilities. Thus, while some studies have implicated CDllc/CD18 in the cytotoxicity mediated by certain T cell dones (20) , others have questioned this involvement (17) . iC3b has also been postulated to be a ligand for CDllc (60) although CDllc/CD18-transfected COS cells fail to bind to this complement factor (3). CDllc/CD18 has also been involved in granulocyte binding to endothelium, although playing only an ancillary role in respect to that of LFA-1 and Mac-1 (61, 62) , and contradictory evidence about the participation of CD11c/CD18 in monocyte adhesion to endothelium has been reported (63, 64) . Our results indicate that CD11c/ CD18 is a receptor for FG on B cells, a fact that has been recently reported on TNF-activated neutrophils (44) . So far, CDllc/CD18 is the only/32 integrin without an identified endothelial ligand, although the existence of such as ligand has been demonstrated with purified CDllc protein (59) . The other two/32 integrins, LFA-1 and Mac-l, share intercellular adhesion molecule 1 (ICAM-1) as a counter-receptor on endothelium, through recognition of different domains of the molecule (65, 66) . The FG-binding ability of Mac-1 and p150,95 follows the same scheme: both are able to interact with the same ligand, although recognizing distinct domains (42, 44) . Given the structural similarity among them, it is tempting to speculate that the three leukocyte integrins can recognize a common set of ligands.
The ability of the mitogenic CDllc mAbs to block B cell binding to FG suggested that FG could be involved in B cell activation. However, FG did not trigger mitogenic responses although it was able to inhibit CDllc mAb-mediated B cell proliferation. This fact could be explained because FG may bind to a CDllc region close, but not identical, to that defined by the mitogenic CDllc mAbs.
In summary, our data constitute the first evidence for the induction of CD11c/CD18 on nontransformed B cells and its involvement on cell activation. The functional capability of certain CDllc mAbs to trigger B cell proliferation and to inhibit FG binding indicate that this integrin plays a role in the regulation of both B cell activation and adhesion processes, mAbs directed to CD11c could exert their mitogenic effects by mimicking the interaction of CDllc with its natural ligand. Whether iC3b or the putative endothelial ligand are able to induce proliferative responses on CD11c § B cells remains to be explored. To that effect, purified endothelial ICAM-1 molecule is able to trigger mitogenic responses by binding to LFA-1 on T cells (15) , and the proliferative effects of other complement factors on normal B lymphocytes and B cell lines have been also documented (67) (68) (69) (70) (71) . The triggering of B cell proliferative responses through CDllc/CD18 by iC3b and endothelium is currently under study in our laboratory.
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